Controversies in the adjuvant therapy of endometrial cancer - Wikidata - awgldk - TriplyDB

Controversies in the adjuvant therapy of endometrial cancer

Controversies in the adjuvant therapy of endometrial cancer

http://www.wikidata.org/entity/Q35238303

about

Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.

P2860

Q39164373-FBB9A1E7-D650-44D3-BA23-AA34E6EFEB31

P2860

Controversies in the adjuvant therapy of endometrial cancer

http://www.wikidata.org/entity/Q35238303

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Controversies in the adjuvant therapy of endometrial cancer

@ast

Controversies in the adjuvant therapy of endometrial cancer

@en

type

label

Controversies in the adjuvant therapy of endometrial cancer

@ast

Controversies in the adjuvant therapy of endometrial cancer

@en

prefLabel

Controversies in the adjuvant therapy of endometrial cancer

@ast

Controversies in the adjuvant therapy of endometrial cancer

@en

P1433

Q35238303-40310B31-B31B-4997-BE20-BEF441B5194B

P1476

Q35238303-5AB8A22A-0445-47EA-8C8F-2DB2F3DA75EB

P2093

Q35238303-EEB4DD1C-ADED-439D-BA4B-633727F0D795

Q35238303-FF3CFE49-E4BF-42BA-A248-2B268B0505F6

P2860

Q35238303-1B8F6A61-7884-4F46-9915-C741D212439E

Q35238303-29A9C926-FF17-4B4B-88AA-50E75FDEFD65

Q35238303-2B1588D9-D0B3-45C3-AFC3-4DF380FE2BAF

Q35238303-3AB0E703-44F5-4F53-94A3-E99EB46C2E70

Q35238303-6150E90B-652D-4E5C-8706-3B837C895D84

Q35238303-6E878D41-690B-4198-AE82-6445DD5ABA15

Q35238303-7DAFF0AE-D940-4FC2-A0A9-A3E3F423A7BB

Q35238303-7ECD1DF8-F20A-4D82-B1B4-BEAB1AE3C852

Q35238303-97CF2292-0337-4176-8773-57E94704B815

Q35238303-A591B9F4-EDE5-4CE3-A32F-4B148F4BC288

P304

Q35238303-65FE4E0B-F81C-4615-B0E1-43BD9B37E220

P31

Q35238303-02C2C39F-7BEF-4AB5-9BF3-6C3A3F901F78

P356

Q35238303-2A57B6E4-8F44-4B18-9CB5-D2306EE02712

P478

Q35238303-B4A23BA2-F833-440D-B834-60A6AC65528E

P577

Q35238303-4904FAE1-45D4-433D-BD83-705948A01516

P5875

Q35238303-0658A48B-E143-4E73-8D34-FF62E5F16B5B

P698

Q35238303-5FE4A3EF-F302-4B6E-A31F-D507A760A20C

P932

Q35238303-71072372-D6DE-4FD9-9461-BE48AB0FD760

P356

P1433

ISRN Obstetrics & Gynecology

P1476

Controversies in the adjuvant therapy of endometrial cancer

@en

P2093

Lin-Hung Wei

http://www.w3.org/2001/XMLSchema#string

Sheng-Mou Hsiao

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant radiotherapy for stage I endometrial cancer

Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients.

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

Conservative management of stage I endometrial carcinoma after surgical staging.

Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial.

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.

P304

724649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5402/2011/724649

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51697376

http://www.w3.org/2001/XMLSchema#string

P698

21977327

http://www.w3.org/2001/XMLSchema#string

P932

3182372

http://www.w3.org/2001/XMLSchema#string